Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
- 1 October 1998
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 105 (10), 1960-1967
- https://doi.org/10.1016/s0161-6420(98)91048-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A Proposed Mechanism for p-Aminoclonidine Allergenicity Based on Its Relative Oxidative LabilityChemical Research in Toxicology, 1997
- Mechanisms of Adrenergic Agonist Induced Allergy Bioactivation and Antigen FormationExperimental Eye Research, 1997
- A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressureSurvey of Ophthalmology, 1996
- Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertensionSurvey of Ophthalmology, 1996
- Preclinical evaluation of brimonidineSurvey of Ophthalmology, 1996
- A 90-Day Study of the Efficacy and Side Effects of 0.25% and 0.5% Apraclonidine vs 0.5% TimololArchives of Ophthalmology (1950), 1996
- Effects of Brimonidine on Aqueous Humor Dynamics in Human EyesArchives of Ophthalmology (1950), 1995
- Long term effect of apraclonidine.British Journal of Ophthalmology, 1995
- Systemic drug interactions with topical glaucoma medicationsSurvey of Ophthalmology, 1990
- SYSTEMIC ADVERSE REACTIONS TO GLAUCOMA MEDICATIONSInternational Ophthalmology Clinics, 1989